Alliance Gears Up For 2024 Heroes in Health Celebration and More

Alliance to Celebrate Heroes in Health

The Alliance invites you to join us at the iconic Waldorf Astoria in Washington, D.C., on September 24 to celebrate Hope, Resilience, and Healthy Aging at our annual Heroes in Health event.

The evening will begin with Conversations with representatives from the U.S. Food & Drug Administration (FDA) and the Centers for Medicare & Medicaid Services (CMS), followed by an awards dinner program honoring trailblazing advocates for aging Americans.

Purchase Tickets

Learn More

Find Out How CMS Can Further Protect Patients in New Report

The Alliance, in partnership with Manatt, has released a report on the Inflation Reduction Act's impact on formularies and utilization management.

The report, “Patient Impact of the Inflation Reduction Act: Administrative Options to Address Changed Incentives for Formulary and Utilization Management” highlights what Centers for Medicare & Medicaid Services (CMS) can do to protect beneficiaries, increase transparency, and ensure prescription drugs are affordable and accessible.

Read Our Press Release

Be sure to tune in to the next episode of our podcast This is Growing Old as we explore the intricacies of the Inflation Reduction Act in depth.​​​​​​

Related News Coverage :
Groups: CMS Has Tools To Fix IRA Formulary Issues That Limit Part D Savings (Inside Health Policy)

CAHC: IRA Will Cause Part D Premium Increases, Less Access To Care (Inside Health Policy)

​​​​​

Discussion About Unintended Consequences of IRA Takes Center Stage

“We can think about drug pricing differently by continuing to be patient-focused…”

Our recent "Medicare & Drug Pricing: Time to Think Differently" program held in partnership with The Hill addressed everything from innovation in treatment to the unintended consequences of drugs and healthcare costs.

Find out what the experts had to say in our event recap.

Related:
Letter to CMS Urges Transparency During Drug Price Negotiation

Lawmakers seek balance between drug costs and innovation (The Hill)

Second Disease-Modifying Therapy
for Alzheimer’s Gains FDA Approval

This month, the FDA approved Kisunla, the second-ever traditional disease-modifying therapy for early, symptomatic Alzheimer's.

Learn more about the latest amyloid plaque-targeting treatment and what this means for those living with this devastating disease.

Read Our Statement

Alliance, 28 Others Advocate for Vaccine Accessibility in Medicare Contracts

Fun in the Sun? Keep Signs of Heat-Related Illness in Mind this Summer

Thank You, Mr. President